New research from the Myasthenia Gravis Rare Disease Network (MGNet). This summary is based on a paper published in the Journal of Neurology on March 23, 2026, titled "Half a century of change: demographic trends and their clinical impact in acetylcholine receptor antibody-positive myasthenia gravis." 

Read the paper here. 

Learn more about MGNet. 

Transcript: 

New research from the Myasthenia Gravis Rare Disease Network (MGNet), a research group of the Rare Diseases Clinical Research Network.

Investigating the Impact of Demographic Trends on Disease Prognosis in Myasthenia Gravis.

This summary is based on a paper published in the Journal of Neurology on March 23, 2026. 

Myasthenia gravis (MG) is a neuromuscular disorder caused by an autoimmune response which compromises nerve muscle communication, causing disabling weakness. In the past 50 years, the epidemiology of MG—how often it occurs in different groups of people and why—has changed over time. However, not much is known about how these changes have impacted management of MG.

In this study, researchers investigated how demographic trends have affected disease prognosis in MG. The team assessed demographics, MG subtypes, and antibody status over 50 years in 1,023 patients with AChR-MG. In 517 patients, the team also evaluated treatment response and adverse events over 20 years.

Results show an increased rate of patients diagnosed with very late-onset MG. Authors note that patients with very late-onset MG may face an increased risk of long-term treatment exposure and adverse events, especially in elderly patients.